Allopurinol remains gout market leader but Uloric making inroads, study finds

Most surveyed rheumatologists, nephrologists and primary care physicians cite increased use of Takeda’s Uloric (febuxostat), in the last six months. In addition, one-third of rheumatologists cite increased use of Savient’s Krystexxa (pegloticase) in the same time period, based on the recent TreatmentTrends: Gout report published by BioTrends Research Group, a unit of Decision Resources.

Uloric outperforms other uric acid lowering (UAL) therapies on most attributes including efficacy, short-term safety/tolerability and ability to be used in patients with a broad range of co-morbidities. After one year on the market, Krystexxa possesses a few competitive advantages over other UAL therapies, including Uloric, but on less important attributes to physicians’ prescribing.

Surveyed rheumatologists, nephrologists and primary care physicians are most satisfied with Uloric compared to other UAL therapies. Despite limited use of Krystexxa in the treatment of gout, roughly half of surveyed rheumatologists and nephrologists are highly satisfied with Krystexxa.